“CEOs You Should Know” is a weekly radio program sponsored by M&T Bank that profiles local companies and their leaders who drive the Greater Washington, D.C. regional economy. As a leader in DC’s business community, iHeart radio invited CEO of American Gene Technologies Jeff Galvin on-air.

This session aired across six broadcast stations--97.1WASH-FM, HOT995, DC101, 98.7 WMZQ, BIG100 and WONK FM--reaching up to 3 million listeners living in Maryland, Virginia and D.C. This interview and the “CEO’s You Should Know” series is available digitally here [ Ссылка ] as well as [ Ссылка ]

If you liked this recording, please subscribe to this Youtube channel here: [ Ссылка ]

About Jeff Galvin:

Jeff Galvin is the CEO and Co-founder of American Gene Technologies (AGT). He earned his BA degree in Economics from Harvard in 1981. He has more than 30 years of business and entrepreneurial experience including founder or executive positions at a variety of Silicon Valley startups. Several of his companies were taken public and/or sold to public companies, including one in the medical-technology arena that was sold to Varian, the leading maker of linear accelerators used in cancer therapy. Following his startup experience, he retired to become an Angel Investor in real estate and high tech. He came out of retirement to found and fund AGT after meeting Roscoe Brady at NIH.

For more information about American Gene Technologies progress in gene and cell therapy research, visit: [ Ссылка ]

American Gene Technologies (AGT) is a gene and cell therapy company with a proprietary gene-delivery platform for rapid development of cell and gene therapies. AGT’s mission is to transform people’s lives by designing highly effective therapeutics to cure infectious diseases, cancers, and inherited disorders. AGT has received three patents for the technology used to make the AGT103-T cell product and ten patents for its unique immuno-oncology approach to stimulate gamma-delta (γδ) T cells to destroy a variety of solid tumors. The company has also developed a synthetic gene for treating Phenylketonuria (PKU), a debilitating inherited disease. AGT's treatment for PKU has been granted Orphan Drug Designation by the Food and Drug Administration (FDA), and it is expected to reach the clinic in 2021.

Follow us on social media for daily updates:
LinkedIn - [ Ссылка ]
Twitter - @americangene, [ Ссылка ]
Facebook - @amerigene, [ Ссылка ]
Instagram - @americangenetechnologies, [ Ссылка ]

свернуть